Century Therapeutics (IPSC) Asset Writedowns and Impairment (2023 - 2025)

Century Therapeutics (IPSC) has 3 years of Asset Writedowns and Impairment data on file, last reported at $6.8 million in Q3 2025.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $6.8 million in Q3 2025; TTM through Sep 2025 was $11.1 million, a 8.69% decrease from a year earlier, with the FY2025 full-year figure at $6.8 million, up 56.3% from the prior year.
• Asset Writedowns and Impairment for Q3 2025 stood at $6.8 million, up from $4.3 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for IPSC reached as high as $12.1 million in Q4 2023 and fell as low as $4.2 million in Q2 2023.
• Historically, Asset Writedowns and Impairment has averaged $6.9 million across 3 years, with a median of $5.5 million in 2024.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 64.37% in 2024 and fell as far as 64.37% in 2024.
• Year by year, Asset Writedowns and Impairment stood at $12.1 million in 2023, then plunged by 64.37% to $4.3 million in 2024, then jumped by 56.3% to $6.8 million in 2025.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $6.8 million in Q3 2025, $4.3 million in Q4 2024, and $12.1 million in Q4 2023.